Alvotech Q1 Earnings Call Highlights

2 hours ago 2

MarketBeat

Thu, May 7, 2026 astatine 8:22 AM CDT 8 min read

Alvotech logo

Key Points

FDA inspection astatine Alvotech’s Reykjavik installation is underway and Biologics License Application resubmissions for aggregate biosimilars are successful the last stage, with the institution readying resubmissions successful Q2 and targeting Q4 approvals.
Facility prime improvements person reduced manufacturing throughput, and Alvotech signed a woody with Fujifilm to adhd U.S. capacity; exertion transportation is underway with merchandise proviso to the U.S. expected successful the 2nd fractional of 2027.
Commercially, AVT02 (Humira biosimilar) is the fastest-growing U.S. Humira biosimilar astatine astir 10% of the biosimilar segment, portion Q1 gross fell 20% to $106 million; absorption reaffirmed full-year gross guidance of $650–$700M and adjusted EBITDA guidance of $180–$220M.
Interested successful Alvotech? Here are 5 stocks we similar better.

Teva Pharmaceuticals Stock: Unlock Value successful This Generic Drug Gem

Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered connected advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercialized enactment globally arsenic the biosimilar developer works done manufacturing enhancements astatine its Reykjavik facility.

FDA inspection underway; resubmissions nearing completion

Founder and Executive Chairman Róbert Wessman said the institution spent the 4th “progressing the FDA resubmission, maintaining a precocious level of inspection readiness, and continuing to grow our commercialized concern globally.” He noted the U.S. Food and Drug Administration began a “routine GMP surveillance inspection” astatine Alvotech’s Reykjavik installation past week, with the inspection “currently ongoing.” Wessman said the institution expects it to reason “by the extremity of concern time tomorrow,” adding that regular surveillance inspections are a mean portion of operating an FDA-regulated manufacturing site.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

2 Generic Drug Makers With Growing Runways

Wessman besides referenced steps taken since the company’s astir caller pre-license inspection successful July 2025. He said Alvotech has implemented “important enhancements crossed our prime strategy and the operations,” and that enactment to code findings is “well advanced.” He added the institution “deliberately taken further clip to substantially de-risk aboriginal operational and regulatory disruption” and to guarantee its resubmissions “fully code the Agency’s requirements.”

According to Wessman, the resubmission of Biologics License Applications for biosimilars to Simponi, SIMPONI ARIA, EYLEA, Prolia, and XGEVA is “now successful the last signifier of completion.” During Q&A, Chief Executive Officer Lisa Graver said the FDA is “on site” and that Alvotech expects the surveillance inspection to adjacent retired this week. Graver said the institution is “on track” to resubmit the pending BLAs successful the 2nd 4th and that the “target is inactive and does stay the 4th quarter” for approvals.

Read Entire Article